Welcome to our dedicated page for Esperion Therape SEC filings (Ticker: ESPR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Esperion Therapeutics, Inc. (ESPR) SEC filings page provides access to the company’s regulatory documents as filed with the U.S. Securities and Exchange Commission. Esperion is a commercial-stage biopharmaceutical company listed on the Nasdaq Stock Market LLC under the symbol ESPR, and its filings offer detailed insight into its cardiometabolic and rare/orphan disease business, including oral non-statin LDL-C therapies such as NEXLETOL and NEXLIZET.
Key filing types for Esperion include annual reports on Form 10-K and quarterly reports on Form 10-Q, which describe the company’s business, risk factors, financial statements, and discussion of operations. Current reports on Form 8-K and 8-K/A, several of which are referenced in the provided data, disclose material events such as financial results, underwritten public offerings of common stock, executive appointments, board changes, and other significant corporate developments.
Investors can also review notifications of late filing on Form 12b-25, which explain delays in periodic reports and provide management’s narrative regarding the status of financial closing procedures. For Esperion, these documents have included explanations related to quarterly financial close and corrections to previously furnished earnings releases.
On Stock Titan, Esperion’s filings are updated in near real time as they are made available on EDGAR. AI-powered summaries help explain the content of lengthy documents, highlight key sections, and surface items such as revenue drivers, commercialization plans for NEXLETOL and NEXLIZET, capital-raising transactions, and changes in executive leadership. Users can also identify trading symbol information, exchange listing details, and other disclosures related to Esperion’s common stock directly from these filings.
Esperion Therapeutics completed the acquisition of Corstasis Therapeutics, making Corstasis a wholly owned subsidiary and adding Enbumyst, an FDA‑approved bumetanide nasal spray for edema in cardiovascular, hepatic and renal disease. The company paid $75,000,000 in upfront cash, with Corstasis equityholders eligible for up to $180,000,000 in milestone payments plus future royalty and licensing‑revenue‑based payments.
To help fund the deal, Esperion amended its credit agreement to add $25,000,000 of new term loans and entered a Royalty Purchase Agreement, selling a portion of Otsuka‑related Bempedoic Acid royalties and milestones to Athyrium for $50,000,000. Athyrium will receive 100% of these specified receivables until it has collected $100,000,000, after which all such payments revert to Esperion.
The Vanguard Group filed Amendment No. 2 to a Schedule 13G/A reporting zero shares of Common Stock of Esperion Therapeutics Inc. as beneficially owned. The filing states 0 shares (0%) and lists zero voting and dispositive powers.
The filing includes a disclosure that certain Vanguard subsidiaries were disaggregated after an internal realignment effective January 12, 2026, and that those subsidiaries will report separately under SEC Release No. 34-39538.
Esperion Therapeutics, Inc. Chief Legal Officer Benjamin Looker reported an open-market sale of 5,708 shares of common stock. The shares were sold at an average price of $2.703 per share to satisfy tax obligations on vested restricted stock units. After this transaction, he directly holds 679,348 shares, indicating that the sale represents a small portion of his overall position.
Esperion Therapeutics’ President and CEO Sheldon L. Koenig reported an open-market sale of 25,578 shares of common stock at $2.719 per share. According to the disclosure, the shares were sold to satisfy tax obligations arising from vested restricted stock units.
After this transaction, Koenig directly holds 2,172,699 shares of Esperion Therapeutics common stock. This filing reflects a tax-related disposition rather than a discretionary reduction of his overall shareholding.
Esperion Therapeutics Chief Financial Officer Benjamin Halladay reported an open-market sale of 6,424 shares of common stock at $2.705 per share. According to the footnote, the shares were sold to satisfy tax obligations on vested restricted stock units. After this tax-related sale, he directly holds 713,602 shares.
ESPR filed a Form 144 reporting a proposed sale of 6,424 shares of Common Stock tied to restricted stock vesting on 03/16/2026. The filing also lists a prior sale of 7,337 shares on 12/17/2025 for 26906.25.
Benjamin Looker/agent files a Form 144 reporting the planned sale of 5,708 shares of Common Stock of ESPR. The filing also discloses prior dispositions of 6,517 shares on 12/17/2025 and 1,689 shares on 01/20/2026, with proceeds shown as $23,897.19 and $4,867.02 respectively. The securities to be sold are listed as restricted stock vesting dated 03/16/2026 and the broker/agent is shown as Fidelity Brokerage Services LLC.
Sheldon Koenig filed a Form 144 reporting an intended sale of 25,578 shares of Common Stock. The shares are described as resulting from restricted stock vesting on 03/16/2026. The filing also discloses prior sales of 48,244 shares on 12/17/2025 for $177,200.21.
The broker of record is Fidelity Brokerage Services LLC at the listed account, and the security is traded on NASDAQ. The filing lists the proposed sale notice date as 03/17/2026.
Esperion Therapeutics Chief Legal Officer Benjamin Looker reported receiving new equity compensation. He was granted a stock option for 269,230 shares of Common Stock at an exercise price of $2.44 per share, expiring on March 13, 2036.
He also received 300,840 shares of Common Stock as a direct grant, bringing his direct Common Stock holdings to 685,056 shares after the award. The stock option award will vest over four years in equal quarterly installments, starting on June 15, 2026.
Esperion Therapeutics, Inc. reported that President and CEO Sheldon L. Koenig received new equity awards. He was granted a stock option covering 647,460 shares of common stock at an exercise price of $2.44 per share, expiring on March 13, 2036, along with 723,760 shares of common stock as a separate award, both at no cash cost to him.
The filing notes that this award will vest over a four-year period in equal quarterly installments beginning on June 15, 2026 Following these grants, Koenig directly holds 2,198,277 shares of Esperion common stock, which includes 3,930 shares recently acquired through Esperion's Employee Stock Purchase Plan.